Approval · Notice of Compliance 24235 · 2020
SOLIQUA: Notice of Compliance 24235
Issued September 17, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 24235
- Date
- September 17, 2020
- Company
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SOLIQUA | Not yet assigned | — |
Medicinal ingredients
- INSULIN GLARGINE 100 UNIT per ML
- LIXISENATIDE 0.033 MG per ML